Grail, the liquid biopsy startup, picks an approach for its cancer test

Grail, the liquid biopsy startup, picks an approach for its cancer test

Source: 
Stat
snippet: 

Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced Monday that it has settled on a method for its test and enrolled 115,000 patients in two large clinical trials. A third study, with 50,000 patients, has already begun.